Johnson & Johnson (JNJ) vs Eli Lilly and Company (LLY)
- Johnson & Johnson JNJ 272.44 −1.40%
- Eli Lilly and Company LLY 1,370.24 −3.37%
Johnson & Johnson and Eli Lilly and Company are both Drug Manufacturers General companies. Eli Lilly and Company is the larger, with a market value of $1.28T against $655.6B — 2.0× the size. Johnson & Johnson trades at the lower P/E: 41.3× against 44.5×. Eli Lilly and Company grew revenue faster over the last twelve months: 45.5% against 7.80%. Eli Lilly and Company has the higher net margin (31.9% vs 16.2%) and the higher return on invested capital (26.4% vs 11.1%). Both pay a dividend; Johnson & Johnson yields more (1.94% vs 0.49%). Across the 23 metrics below, Eli Lilly and Company leads on 12 and Johnson & Johnson on 11.
Valuation
Profitability
| Metric | JNJ | LLY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 67.56% | 83.64% | 73.01% |
| Operating margin | 19.72% | 40.27% | 18.34% |
| Net margin | 16.20% | 31.90% | 7.31% |
| Free cash flow margin | 21.13% | 22.74% | 18.52% |
| Return on equity | 20.02% | 86.02% | 5.80% |
| Return on assets | 8.25% | 20.97% | 2.28% |
| Return on invested capital | 11.07% | 26.42% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack